Search

Displaying results 1661 - 1670 of 2420 in total
  1. Drug

    Aficamten

    go.drugbank.com/drugs/DB18490
    ApprovedInvestigational

    Aficamten is a cardiac myosin inhibitor. Approved by the FDA on December 19, 2025, aficamten is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symp...

    Categories: Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 Substrates
  2. Drug

    Bucindolol

    go.drugbank.com/drugs/DB12752
    Investigational

    Bucindolol has been investigated in Heart Failure.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates
  3. Drug

    Zoliflodacin

    go.drugbank.com/drugs/DB12817
    ApprovedInvestigational

    Gonorrhea, caused by Neisseria gonorrhoeae, presents a significant public health challenge due to increasing antimicrobial resistance. Zoliflodacin is a first-in-class spiropyrimidinetrione antibiotic designed to address this need by inh...

    Categories: Cytochrome P-450 CYP1A2 Substrates, Cytochrome P-450 Substrates
  4. Drug

    Secnidazole

    go.drugbank.com/drugs/DB12834
    ApprovedInvestigational

    Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including DB00916 and DB00911, but displays improved oral absorption and a longer terminal elimination half-l...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsProducts: SECNIDAZOL 500 MG POLVO P RECONSTRUIR, SECNIDAZOL 750 MG POLVO P. RECOSTRUIR
  5. Drug

    Grapiprant

    go.drugbank.com/drugs/DB12836
    InvestigationalVet approved

    Grapiprant, also known as AT-001 and CJ-023, is a drug from the piprant class. These molecules were derived from acylsulfonamide and are characterized to be a novel series of para-N-acylaminomethylbenzoic acid known to be prostaglandin r...

    Categories: P-glycoprotein substrates
  6. Drug

    Tazemetostat

    go.drugbank.com/drugs/DB12887
    ApprovedInvestigational

    Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA app...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  7. Drug

    Resmetirom

    go.drugbank.com/drugs/DB12914
    ApprovedInvestigational

    Resmetirom is a thyroid hormone receptor-beta (THR-beta) agonist. On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alc...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Inhibitors
  8. Drug

    Gallopamil

    go.drugbank.com/drugs/DB12923
    Investigational

    Gallopamil has been used in trials studying the treatment of Asthma.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  9. Drug

    Cafedrine

    go.drugbank.com/drugs/DB12926
    Investigational

    Cafedrine is under investigation in clinical trial NCT01311414 (Effect of Cafedrine/Theodrenaline and Urapidil on Cerebral Oxygenation).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  10. Drug

    Theodrenaline

    go.drugbank.com/drugs/DB12927
    Investigational

    Theodrenaline is under investigation in clinical trial NCT01311414 (Effect of Cafedrine/Theodrenaline and Urapidil on Cerebral Oxygenation).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates